Details for Patent: 12,622,921
✉ Email this page to a colleague
Which drugs does patent 12,622,921 protect, and when does it expire?
Patent 12,622,921 protects TEPYLUTE and is included in one NDA.
This patent has nine patent family members in eight countries.
Drugs Protected by US Patent 12,622,921
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shorla | TEPYLUTE | thiotepa | SOLUTION;INTRAVENOUS | 216984-001 | Jun 25, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ADENOCARCINOMA OF THE BREAST OR OVARY | ⤷ Start Trial | ||||
| Shorla | TEPYLUTE | thiotepa | SOLUTION;INTRAVENOUS | 216984-002 | Feb 26, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ADENOCARCINOMA OF THE BREAST OR OVARY | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,622,921
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2023220025 | ⤷ Start Trial | |||
| Canada | 3244102 | ⤷ Start Trial | |||
| China | 119053320 | ⤷ Start Trial | |||
| European Patent Office | 4479024 | ⤷ Start Trial | |||
| Japan | 2025506736 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
